Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elacestrant companion diagnostic - Guardant Health

Next Previous
Drug Profile

Elacestrant companion diagnostic - Guardant Health

Alternative Names: Elacestrant Guardant360® CDx companion diagnostic

Latest Information Update: 18 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guardant Health
  • Developer Guardant Health; Radius Health Inc.
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III HER2 negative breast cancer

Most Recent Events

  • 22 Aug 2024 Stemline Therapeutics in collaboration with Radius Health completes the phase-III EMERALD trial in Her2 negative Breast cancer (Diagnosis) in USA, United Kingdom, Spain, Portugal, South Korea, Italy, Israel, Ireland, Hungary, Greece, France, Denmark, Canada, Belgium, Austria, Australia, Argentina (unspecified route) , (NCT03778931)
  • 08 Dec 2022 Gaurdant Health and AstraZeneca agree to co-develop elacestrant Guardant360® CDx companion diagnostic for Breast cancer
  • 13 Oct 2022 Elacestrant companion diagnostic is still in phase III trials for Breast cancer (Diagnosis) in Italy, South Korea, Portugal, Spain, United kingdom and USA, France, Greece, Hungary, Ireland, Israel, Argentina, Australia, Austria, Belgium, Canada, Denmark (Radius Therapeutics pipeline, October 2022)(NCT03778931)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top